﻿<?xml version="1.0" encoding="utf-8"?><!--RSS Genrated: Sun, 05 Apr 2026 07:10:31 GMT--><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:ev="http://purl.org/rss/1.0/modules/event/"><channel><title>American Pharmacists Association</title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/September-2022/rss/3514</link><atom:link href="http://www.pharmacist.com/Publications/Pharmacy-Today/September-2022/rss/3514" rel="self" type="application/rss+xml" /><description>RSS document</description><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[New therapeutic agents marketed in 2021: Part 2]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/new-therapeutic-agents-marketed-in-2021-part-2</link><description><![CDATA[  Daniel A. Hussar, PhD  

   

 Part 1 ( Pharmacy Today , May 2022) of this series on new FDA-approved therapeutic agents marketed in 2021 reviewed 4 new therapeutic agents: atogepant ...]]></description><pubDate>Sun, 07 Aug 2022 16:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/new-therapeutic-agents-marketed-in-2021-part-2</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-3348]]></dc:identifier></item></channel></rss>